Fundraising FoxBioAdvance — 2026 Investments
3 investments dated 2026 · listed companies and verified rows first · show all
Latus develops gene therapy research and development capabilities leveraging cell and gene therapy expertise.
AI & Machine LearningBiotechDeep TechHealthtechPhiladelphia, US
Co-investorsHatch BioFund8VCDCVC (Data Collective)DCVC BioGaingelsKorea Development Bank+1 more
__Twitter.png)
Tolerance Bio develops therapeutics targeting the thymus—the regulator of immune tolerance—to preserve, restore, and manipulate its function and extend health span.
BiotechDeep TechLongevityPhiladelphia, US
Francisco Leon(Executive Officer, Director)inPhilip Ball(Executive Officer, Director)Justin Vogel(Executive Officer, Director)in
BoardDamia Tormo Carulla(Director)Pablo Cironi(Director)inRobert Goldstein(Director)
Co-investorsCriteria Bio VenturesBen Franklin Technology PartnersColumbus Venture Partners
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.